1. Scrip
  2. >>Conferences
  3. >>ESMO

ESMO 24: Genmab Has AbbVie In Its Sights As Rina-S Shines In Ovarian Cancer

 
• By Kevin Grogan

The Copenhagen-headquartered group is taking its antibody-drug conjugate rinatabart sesutecan into Phase III and chief medical officer Tahi Ahmadi tells Scrip that it has the potential to treat far more women than the only currently marketed FRα-targeting ADC, AbbVie's Elahere.

Genmab Office Copenhagen - close up
• Source: Genmab

Genmab A/S‘s acquisition of antibody-drug conjugate (ADC) specialist ProfoundBio (Suzhou) Co., Ltd. earlier this year for $1.8bn in cash is looking like a shrewd bit of business following new data on rinatabart sesutecan (Rina-S) which showed an encouraging response rate in heavily pretreated patients with ovarian cancer.

The Danish biotech gave an update at the European Society for Medical Oncology meeting in Barcelona from the dose expansion part of an ongoing 42-patient Phase I/II trial of Rina-S, a folate receptor-alpha (FRα)-targeted Topo-1 ADC. In patients receiving the 100mg/m2 (n=22), the results showed a confirmed objective response rate (ORR) of 18.2% but this climbed to 50

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ESMO

ESMO 24: SunRISes On J&J’s TAR-200 In Bladder Cancer

 
• By Alexandra Shimmings

J&J acquired Taris in 2019 to gain access to TAR-200 and its drug delivery platform. Now, early clinical data suggest the product could delay or remove the need for cystectomy in several bladder cancer settings and the US healthcare giant is eyeing multi-blockbuster sales.    

ESMO 24: CDK2 Inhibitors - Where Next For The Novel Class?

 
• By Alexandra Shimmings

The Barcelona meeting saw early data from two candidates from Incyte and Pfizer which suggest some progress for a new drug mechanism that has so far underwhelmed.    

ESMO 24: Investors Are Starting To Believe In BioNTech’s Cancer Drugs

 
• By Andrew McConaghie

The company’s investment in oncology is starting to pay off, with its PD-L1/VEGF inhibitor BNT324 generating particular interest at ESMO.

ESMO 24: Bayer Prostate Drugs Old And New Deliver On Survival

 
• By Kevin Grogan

The German group's goal of expanding Nubeqa into wider prostate cancer patient populations has probably been reached with the results from the Phase III ARANOTE study, while a combination of its older product Xofigo and Pfizer and Astellas’ Xtandi is set to become standard of care for another subset.

More from Leadership

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

Soriot Cautions Europe Amid More US Expansion

 
• By Kevin Grogan

The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By Vibha Ravi

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs